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Management of Intestinal Transplantation in Humans 
K. Abu-Elmagd, J.J. Fung, J. Reyes. A. Casavilla. D.H. Van Thiel, Y. Iwaki. V. Warty, N. Nikolaidis. 
J. Block. K. Nakamura. B. Goldbach. J. Demetris. A. Tzakis. S. Todo. and T.E. Starzl 
WE report here the clinical experience and manage-
ment guidelines for the nine consecutive cases who 
received either an isolated small intestinal graft (n = I) or 
an intestine liver combination at the University of Pitts-
burgh, with FK 506 being the basic immunosuppressive 
drug therapy. 
MATERIALS AND METHODS 
The pretransplant clinical features and patient characteristics are 
fully described elsewhere in this issue.' In brief. three of the 
recipients were young adults and six were children. The donors 
were ABO-identical and HLA-histoincompallble. and cytotoxic 
crossmatches were positive in two cases. Donor and reCipient 
were of the opposite sex to four of the cases. Attempts were made 
at selective decontamination of the donors with no efforts to alter 
the graft Iymphoreticular tissue with antilymphocyte preparations 
or other modalities. 
The principles of the donor operations and the techniques for 
both isolated intestinal transplantation and a composite intestine-
liver graft are described elsewhere. Z.J Continuity of the gastroin-
testinal tract was restored in stages. Eight to 16 weeks later. the 
vent-chimneys were excised at a second operation. 
The basic immunosuppressive therapy was FK 506. The drug 
was given intravenously (IV) at first with 0.1 to 0.15 mglkg per day 
and enterally later at a starting dose of 0.3 mglkg per day in two 
divided doses as described elsewhere.4 Dose adjustments were 
made based upon the quality of liver function. evidence of graft 
rejection. development of renal dysfunction. and daily FK 506 
trough plasma levels. Prednisone was given at the outset in all but 
one pediatric case. Prophylactic steroid recycle was given to one 
adult recipient with a strong positive cytotoxic crossmatch. A low 
dose of azathioprine (I to 2 mgtkg per day) was added in 
combination with FK 506 in one adult and one pediatric case. 
Assessment of graft function and detection of graft rejection 
was based prirnarily upon clinical. biochemical. histopathologic. 
endoscopic. radiologic. and metabolic parameters. These included 
thorough clinical evaluation. serial graft biopsies. periodic Gl 
series. frequent anthropometric measures. serial serum protein 
and fatty acid analyses. FK 506 oral kinetics. D-xylose. and 
vitamin E absorption tests. 
Frequent blood and quantitative stool cultures were also ob-
tained. and the results compared for similarity and dissimilarity of 
the intestinal flora. Selective decontamination was used for 4 to 6 
weeks after transplantation and during rejection episodes.' 
RESULTS 
The clinical course and total outcome of the nine patients 
are fully described in the current symposium by Tzakis et 
al. I Eight patients are currently alive and one pediatric 
recipient died of graft-versus-host disease (GVHD) 23 days 
after a combined liver-intestine transplantation. 
The convalescence of all of our patients. particularly the 
isolated small bowel recipient. was difficult. requiring 
protracted hospitalization. Consequently. the achievement 
of alimentation was a slow process requiring 6 weeks to 9 
months after transplantation. 
The adopted histological criteria for the diagnosis of 
acute intestinal graft rejection included significant cellular 
infiltration. cryptitis. villous edema with abrasion. and 
even sloughing of the cell surface epithelium. Six of the 
nine grafts experienced one to eight episodes of rejection. 
The frequency and severity of hepatic graft rejection in 
these patients was similar to that in simple liver graft 
recipients. Interestingly. the most serious and persistent 
graft rejections were in the isolated smail bowel and 
positive cytotoxic crossmatch recipients. The histological 
changes suggestive of chronic graft rejection were not 
evident in any of the endoscopic mucosal biopsies. 
In most of the rejection episodes. the clinical. endo-
scopic. and radiologic pictures correlated with the con-
comitant histological findings. Clinically, most of the re-
jection episodes were presented with fever. high stomal 
output/diarrhea. dusky mucosa and graft ileus. A septic 
shock-like syndrome was also a concomitant finding in 
patients with severe rejection crisis. 
The attacks of graft rejection were successfully treated 
with FK 506 dose augmentation and. less frequently, by 
steroid bolus and recycle. OKT3 was required only in the 
patient with isolated intestinal graft. Recovery of the 
intestinal mucosal changes was complete in all patients. 
GVHD was unequivocally diagnosed in a combined 
liver-intestine pediatric recipient using the standard histo-
logical and in situ hybridization techniques. Because the 
donor and recipient were opposite sexes. karyotyping 
provided a definitive cross-check of the other techniques. 
Light immunosuppression was attempted early in the 
course because of disruption of the upper enteric anasto-
mosis and consequent soilage. In this patient. the skin 
lesions started to appear 10 days after transplant, and the 
clinical picture simulated that of life-threatening sepsis. 
Therefore. immunosuppression was significantly reduced 
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and 13 days later the patient succumbed to multiple-organ 
failure. 
Serial evaluation of the anthropometric parameters 
(weight, upper-arm measurement of fat and muscle), the 
need for IV nutrition, and the conduction of different 
absorption and metabolic studies were used for the assess-
ment of graft function. The intermittent reinstitution of 
panial or complete IV nutrition was primarily due to either 
prominent intestinal graft reje.ction or severe systemic/ 
enteric infection. Interestingly t complete oral administra-
tion of the standard FK 506 dose was able to maintain a 
therapeutic plasma level in all patients within the first 4 
postoperative weeks. D-Xylose was adequately absorbed 
by the intestinal graft in most of the studied patients (11 = 
7). However. vitamin E absorption was slightly depressed 
in most cases. Posttransplant serum JgA levels were within 
the normal range for both the pediatric and adult recipi-
ents. 
Recovery of the intestinal graft motility was clinically. 
radiologically. and endoscopically documented I to 2 
weeks after transplantation. Temporary dysfunction of the 
gastrointestinal motility in the form of gastric atony (n = 
1). pylorospasm (n = 2). and gastroesophageal reflux (n = 
3) were observed during the first 3 postoperative months. 
Five episodes of translocation (4 bacterial. 1 fungal) 
developed in a total of three patients. Severe rejection of 
the intestinal graft was concomitant on only one occasion. 
Treatment was successful in all cases with the specific 
systemic antibiotics and proper intestinal decontamina-
tion. 
DISCUSSION 
Our experience suggests that small bowel transplantation 
in humans could become more practical with the clinical 
use of FK 506. However. development of allograft rejec-
tion was still a major potential barrier to successful clinical 
small intestinal transplantation. In the current study, the 
clinical. endoscopic, histologic. radiologic. and metabolic 
parameters were effective in detecting acute graft rejection 
early enough to be successfully treated with complete 
healing of the intestinal mucosa. Simultaneous evaluation 
of the circulating lymphokines, the brush-border enzy-
matic activities. and the expression of the major histo-
compatibility complex (MHC) class II antigen on the 
enterocytes may make possible an even earlier immuno-
histochemical diagnosis. Augmented FK 506 and steroid 
therapy was effective in reversing most of the rejection 
episodes. 
The infectious implications of rejection have been pre-
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viously demonstrated with liver transplantation.6•7 The 
paradoxical therapeutic philosophy of treating infection 
(related to rejection) with increased immunosuppression is 
designed to stop or prevent bacterial translocation. The 
concept is even more applicable with the intestine than 
with the liver. because a disrupted mucosal barrier quickly 
creates a lethal environment for the total body. Proper 
adjustment of the immunosuppressive therapy combined 
with efficient antibiotic treatment was successful in all of 
our morbid cases except in the child who died of GVHD. 
GVHD may complicate the early and late postoperative 
course of intestinal transplant recipients. particularly those 
with inadequate immunosuppressive therapy. Such mor-
bidity is better understood in view of the striking phenom-
enon of cell migration and repopulation which was recently 
described.l •8 .9 Early diagnosis of GVHD and prompt ad-
justment of the immunosuppressive treatment should be 
effective in such cases. as has been described recently with 
FK 506 after experimental bone marrow transplantation. 10 
The anthropometric measures. oral FK S06 kinetic stud-
ies. serum protein and fatty acid analyses. and D-xylose 
tolerance test seem to be reliable indices for the assess-
ment of the quality of graft function. Monitoring of the 
gastrointestinal motility of both the grafted and recipient 
intestinal segments with thorough evaluation of the graft 
neuroendocrine functions are currently under evaluation. 
In conclusion. the current results underscore the possi-
ble clinical utility of intestinal transplantation, particularly 
in continuity with the liver, but emphasize equally the 
complexity and difficulty of management in these cases. 
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